New Research- Long term use of MAO-B inhibitors may slow Parkinson's progression
Researchers from the University of South Florida found in a retrospective analysis of clinical trial data that long-term use of monoamine oxidase type B, or MAO-B, inhibitors slows the clinical decline of patients with Parkinson's disease.
Parkinson's decline slowed with extended MAO-B inhibitors - UPI.com |
Unfortunately, the paper on which this report is based [1] is behind a paywall. But, Medicalxpress are reporting [2]:
"A one year increase in duration of MAO-B inhibitor exposure was associated with a benefit equivalent in magnitude to approximately 20% of the annual decline in Activities of Daily Living, Ambulatory Capacity, and Global Disability observed in participants not receiving an MAO-B inhibitor." References: [1] "Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson’s Disease: An Analysis of NET-PD LS1" Hauser Robert, et al. Journal of Parkinson's Disease, 2017 Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson’s Disease: An Analysis of NET-PD LS1 - IOS Press [2] Extended use of MAO-B inhibitors slows decline in Parkinson's disease patients John |
All times are GMT -5. The time now is 06:11 AM. |
Powered by vBulletin Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.
vBulletin Optimisation provided by
vB Optimise v2.7.1 (Lite) -
vBulletin Mods & Addons Copyright © 2024 DragonByte Technologies Ltd.